CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CHEMOTHERAPY ALONE IN NON-SMALL CELL LUNG CANCER WITH PD-L1≥ 1 %: A SUBGROUP ANALYSIS FROM THE EMPOWER-LUNG 3 PART 2 TRIAL.

RIPRETINIB IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOURS (INVICTUS): A DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED, PHASE 3 TRIAL.

OMISSION OF RADIOTHERAPY AFTER BREAST-CONSERVING SURGERY FOR WOMEN WITH BREAST CANCER WITH LOW CLINICAL AND GENOMIC RISK: 5-YEAR OUTCOMES OF IDEA

NODAL BURDEN AND ONCOLOGIC OUTCOMES IN PATIENTS WITH RESIDUAL ISOLATED TUMOR CELLS AFTER NEOADJUVANT CHEMOTHERAPY (ypN0i+): THE OPBC-05/ICARO STUDY

UGT1A1*28 POLYMORPHISM AND THE RISK OF TOXICITY AND DISEASE PROGRESSION IN PATIENTS WITH BREAST CANCER RECEIVING SACITUZUMAB GOVITECAN.